

EQA round: AT2/24 - Autoantibodies in Thyroid Diseases

Deadline: 25.10.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(576) anti-microsomes (TPO)	[kU/L]				200							193	154	80
Sample A1		9,22	10	110	200							193	160	83
(1) Abbott		0,561	0,33	59	65	0	CVPG 0,561	0,1	50%	0,28	0,842	65		
(12) Beckman Coulter		4,16	0,66	16	22	0	CVPG 4,16	0,35	50%	2,08	6,24	22		
(29) Siemens (Immulin)		84,8	7,7	9,1	9	0	CVPG 84,8	9,5	50%	42,4	128	9		
(60) Roche		10,9	3,4	31	67	0	CVPG 10,9	1	50%	5,45	16,4	67		
(162) Siemens (Atellica)		29	1,9	6,4	19	0	CVPG 29	1	50%	14,5	43,5	19		
(179) Siemens		28	0	0	11	0	CVPG 28		50%	14	42	11		
Other					7	1						0		
							1x 15, 3x 25, 1x 52, 1x 135, 1x 166							
Sample B1		662	220	33	200							193	185	96
(1) Abbott		748	55	7,3	65	0	CVPG 748	17	50%	374	1130	65		
(12) Beckman Coulter		485	69	14	22	0	CVPG 485	36	50%	242	728	22		
(29) Siemens (Immulin)		729	78	11	9	0	CVPG 729	96	50%	364	1100	9		
(60) Roche		504	83	16	67	0	CVPG 504	25	50%	252	756	67		
(162) Siemens (Atellica)		1320	46	3,4	19	0	CVPG 1320	26	50%	660	1980	19		
(179) Siemens		1300	0	0	11	0	CVPG 1300		50%	650	1950	11		
Other					7	1						0		
							1x 15, 3x 25, 1x 52, 1x 135, 1x 166							
(575) anti-thyreoglobulin	[kU/L]				194							187	162	87
Sample A1		7,66	9,6	130	194							187	163	87
(1) Abbott		0,836	0,15	18	63	0	CVPG 0,836	0,046	50%	0,418	1,26	63		
(12) Beckman Coulter		0,722	0,59	81	21	0	CVPG 0,722	0,31	50%	0,361	1,09	21		
(29) Siemens (Immulin)		20	0	0	8	0	CVPG 20		50%	10	30	8		
(60) Roche		17,6	2,2	13	65	0	CVPG 17,6	0,68	50%	8,8	26,4	65		
(162) Siemens (Atellica)		1,3	0	0	21	0	CVPG 1,3	0	50%	0,65	1,95	21		
(179) Siemens		0,95	0,52	55	9	0	CVPG 0,95	0,64	50%	0,475	1,43	9		
Other					7	1						0		
							1x 15, 2x 25, 1x 36, 1x 52, 1x 135, 1x 166							
Sample B1		645	600	93	194							187	184	98
(1) Abbott		316	23	7,3	63	0	CVPG 316	7,2	50%	158	474	63		
(12) Beckman Coulter		171	11	6,7	21	0	CVPG 171	6,1	50%	85,5	257	21		
(29) Siemens (Immulin)		451	78	17	8	0	CVPG 451	59	50%	225	677	8		
(60) Roche		1370	92	6,7	65	0	CVPG 1370	28	50%	685	2060	65		
(162) Siemens (Atellica)		183	9,8	5,3	21	0	CVPG 183	5,2	50%	91,5	275	21		
(179) Siemens		188	12	6,2	9	0	CVPG 188	14	50%	94	282	9		
Other					7	1						0		
							1x 15, 2x 25, 1x 36, 1x 52, 1x 135, 1x 166							
Set 2														
(590) anti-TSH receptor	[U/L]				105							100	97	97
Sample A2		0,819	0,13	16	105							100	98	98
(1) Abbott		1,38	0,3	22	20	0	CVPG 1,38	0,16	33%	0,924	1,84	20		
(29) Siemens (Immulin)		0,1	0	0	10	0	CVPG 0,1	0	100%	0	0,2	10		
(60) Roche		0,8	0	0,05	70	0	CVPG 0,8	0	100%	0	1,6	70		
Other					5	0						0		
							1x 24, 1x 36, 2x 73, 1x 87							
Sample B2		4,17	1	24	105							100	98	98
(1) Abbott		5,76	0,28	4,9	20	0	CVPG 5,76	0,16	33%	3,85	7,67	20		
(29) Siemens (Immulin)		0,162	0,026	16	10	0	CVPG 0,162	0,02	100%	0	0,324	10		
(60) Roche		4,06	0,35	8,5	70	0	CVPG 4,06	0,1	33%	2,72	5,4	70		
Other					5	0						0		
							1x 24, 1x 36, 2x 73, 1x 87							